

SynAct Pharma

Approaching a catalyst-rich period

SynAct Pharma's **Q325 results** underscored the company's steady progress on its clinical strategy, led by the ongoing Phase IIb ADVANCE trial evaluating resomelagon as a first-line treatment for rheumatoid arthritis (RA). The study remains on track to complete enrolment by end-FY25, with top-line data anticipated in Q126. Operating performance reflected this acceleration, with operating expenses increasing 45.5% y-o-y (16.6% q-o-q) to SEK35.4m, reflecting higher R&D spend (+44.3% y-o-y; +18.6% q-o-q to SEK28.1m) as development activities ramp up. We anticipate a similar cost trajectory in Q425, followed by a moderation in 2026 after the Phase IIb readout. The SEK34.4m cash injection from warrant conversions in Q3 has strengthened the balance sheet with headroom to complete the ongoing Phase II studies, with further flexibility from the SEK30m credit facility to potentially initiate scoping exercises in other indications, such as RA-flares and virus-driven acute inflammatory conditions. Following our recent initiation, we reiterate our valuation of SEK1.97bn or SEK36.9/share.

Year end	Revenue (SEKm)	PBT (SEKm)	EPS (SEK)	DPS (SEK)	P/E (x)	Yield (%)
12/23	0.0	(149.7)	(4.34)	0.00	N/A	N/A
12/24	0.0	(90.8)	(2.08)	0.00	N/A	N/A
12/25e	0.0	(122.8)	(2.24)	0.00	N/A	N/A
12/26e	0.0	(56.4)	(0.91)	0.00	N/A	N/A

Note: PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Near-term readouts to define strategy

As the ADVANCE trial (n=240) approaches completion, we expect the most important near-term inflection point for SynAct to be the top-line readout in Q126, allowing the company to kickstart partnering discussion for resomelagon. We also believe that with infection-driven acute inflammation becoming increasingly central to the company strategy, data from the Phase II RESOVIR-2 study in dengue (patient recruitment to initiate in Brazil in Q126 with results in Q226) will play a crucial role in further establishing resomelagon's value proposition as a potential treatment for both chronic and acute inflammation and defining SynAct's positioning with potential partners. We continue to see polymyalgia rheumatica (PMR) as an additional upside driver for the programme (Phase II to initiate in Q425 in Denmark).

Cash position strengthened

SynAct ended Q325 with a net cash balance of SEK77.9m, supported by SEK34.4m cash inflows from two separate TO2 warrant conversions by Heights Capital Management (HCM) in July and August, respectively. The company also holds a SEK30m bridge facility with Hunter Capital (undrawn to date), providing incremental flexibility if required. Based on SynAct's announced clinical activities and our projected burn rates, we estimate the company to be funded into 2027, well past the near-term catalysts expected in 2026.

Valuation: Maintain at SEK1.97bn or SEK36.9/share

We recently initiated coverage on SynAct and reiterate our valuation of SEK1.97bn or SEK36.9 per share following the Q325 results.


Q325 results

Pharma and biotech

31 October 2025

Price	SEK23.05
Market cap	SEK1,136m
	SEK9.42/\$
Net cash/(debt) at 30 September 2025	SEK77.9m
Shares in issue	53.3m
Code	SYNACT
Primary exchange	OMX
Secondary exchange	N/A

Share price performance



%	1m	3m	12m
Abs	(2.7)	(3.0)	138.0
52-week high/low	SEK25.3	SEK7.3	

Business description

SynAct Pharma is a clinical-stage biotechnology company focused on the development of treatments to resolve, rather than inhibit, ongoing inflammatory processes in acute and chronic diseases.

Next events

PMR Phase II trial launch	Q425
ADVANCE Phase IIb RA trial results	Q126
RESOVIR-2 Phase II dengue trial completion	Q226

Analysts

Jyoti Prakash, CFA	+44 (0)20 3077 5700
Arron Aatkar, PhD	+44 (0)20 3077 5700

healthcare@edisongroup.com

[Edison profile page](#)

SynAct Pharma is a research client of Edison Investment Research Limited

Financials and valuation

Operating performance: No surprises in Q325

SynAct's Q325 results were broadly in line with expectations and reflected the company's ongoing efforts in advancing resomelagon through proof-of-concept studies in multiple indications. The immediate focus for the company remains the Phase IIb ADVANCE study (double blinded, placebo-controlled study evaluating resomelagon as a first-line treatment in newly diagnosed RA patients, in combination with standard-of-care methotrexate), which is nearing completion of patients enrolment (n=240) in Q425 (top-line results expected in Q126).

In Q325, SynAct reported an operating loss of SEK35.4m, up 45.5% y-o-y and 16.6% q-o-q. This was primarily driven by increased R&D expenses related to the ADVANCE trial (which had commenced in September 2024), which we believe may be due to accelerated patient enrolment for the study. Given that both the RESOVIR-2 study and the upcoming Phase II study in PMR are investigator sponsored, with patient enrolment in RESOVIR-2 expected to commence only in Q126 (dengue season in Brazil), we expect limited R&D spend on these by SynAct in Q325. As expected, R&D expenses during the quarter made up the bulk of the operating expenses (c 80%) coming in at SEK28.1m (up 44.3% y-o-y and 18.6% q-o-q). We expect this trend to continue in Q425. G&A expenses have normalised over the past few quarters with SEK7.8m recorded in Q325 (+16.1% q-o-q). Operating cash outflow for the period was SEK25.8m, benefiting from a favourable working capital position.

Following the Q325 results, we keep our estimates for SynAct unchanged except for the FY25 R&D expense estimate, which we raise modestly to SEK94.9m, from SEK90.4m previously. We now estimate an operating loss of SEK121.5m in FY25 for SynAct (SEK117.0m previously). We maintain our FY26 forecasts and long-term assumptions.

Balance sheet: Healthier following the SEK34.4m cash injection

Given the front-end loaded nature of clinical development and long lead times to the market, capital adequacy is a key consideration for development-stage biotech companies. We note that SynAct has been successful in the past in raising capital at favourable terms, allowing it to maintain sufficient runway to progress its plans in a timely and efficient manner. The company ended Q325 with net cash of SEK77.9m (no debt on books), supported by warrant conversions by HCM during the quarter (1m warrants converted each in July and August 2025 for total proceeds of SEK34.4m). SynAct also holds a SEK30m credit line with Hunter Capital, which can be drawn down up to 31 December 2026. Given the current visibility on the company's near-term plans, we believe a drawdown may not be required although, should the company decide to self-undertake further scoping exercises or clinical work in RA flares or other virus-induced acute conditions in 2026, these funds may provide the required initial support. We note, however, that further funding will be required to advance and complete any such additional study. Based on current visibility, we estimate SynAct to have a cash runway into 2027.

Valuation: Reiterated at SEK1.97bn or SEK36.9 per share

We recently initiated coverage on SynAct and keep our valuation unchanged at SEK1.97bn or SEK36.9 per share following the Q325 results (Exhibit 1). We direct readers to our [initiation note](#) for details on the assumptions and drivers for our valuation. We expect the next significant inflection point for SynAct to be the top-line results from the ADVANCE trial in Q126.

Exhibit 1: SynAct rNPV valuation

Product	Indication	Expected launch	Peak sales (\$m)	NPV (SEKm)	Probability	rNPV (SEKm)	rNPV/share (SEK)
Resomelagon	Rheumatoid arthritis – newly diagnosed patients	2031	2,300	5,532.0	30%	1,593.9	29.9
	Rheumatoid arthritis – flares	2032	1,000	2,189.3	15%	301.2	5.6
	Respiratory viral-infections	2031	250	678.6	15%	101.8	1.9
	Polymyalgia rheumatica	2032	180	377.1	10%	29.0	0.5
Direct costs to 2035 less tax				(137.8)		(137.8)	(2.6)
Net cash at end-September 2025				77.9		77.9	1.5
Valuation				8,717.1		1,966.1	36.9

Source: Edison Investment Research

Exhibit 2: Financial summary

Year end 31 December	SEKm	2022	2023	2024	2025e	2026e
		IFRS	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS						
Revenue		0.00	0.00	0.00	0.00	0.00
Licensing income		0.00	0.00	0.00	0.00	0.00
Royalties		0.00	0.00	0.00	0.00	0.00
Others		0.00	0.00	0.00	0.00	0.00
Cost of Sales		0.00	0.00	0.00	0.00	0.00
Gross Profit		0.00	0.00	0.00	0.00	0.00
R&D expenses		(70.07)	(105.06)	(49.31)	(94.87)	(27.59)
G&A expenses		(35.61)	(44.83)	(40.49)	(26.64)	(27.17)
EBITDA		(104.64)	(149.18)	(89.36)	(120.86)	(54.08)
Operating Profit (before amort. and except.)		(105.71)	(149.94)	(89.98)	(121.51)	(54.76)
Intangible Amortisation/impairment		0.00	(74.56)	0.00	0.00	0.00
Exceptionals		0.00	0.00	0.00	0.00	0.00
Other		0.00	0.00	0.00	0.00	0.00
Operating Profit		(105.71)	(224.50)	(89.98)	(121.51)	(54.76)
Net Interest		(1.36)	0.22	(0.85)	(1.32)	(1.65)
Profit Before Tax (norm)		(107.07)	(149.72)	(90.82)	(122.82)	(56.41)
Profit Before Tax (reported)		(107.07)	(224.28)	(90.82)	(122.82)	(56.41)
Tax		7.86	8.47	8.42	8.14	8.14
Profit After Tax (norm)		(99.21)	(141.25)	(82.40)	(114.68)	(48.27)
Profit After Tax (reported)		(99.21)	(215.81)	(82.40)	(114.68)	(48.27)
Average Number of Shares Outstanding (m)		27.59	32.52	39.53	51.17	53.33
Basic EPS - normalised (SEK)		(3.60)	(4.34)	(2.08)	(2.24)	(0.91)
Basic EPS - reported (SEK)		(3.60)	(6.64)	(2.08)	(2.24)	(0.91)
BALANCE SHEET						
Fixed Assets		2.37	152.96	156.67	156.03	155.35
Intangible Assets		0.00	152.16	154.59	154.59	154.59
Tangible Assets		2.10	0.66	1.94	1.29	0.61
Investments		0.27	0.14	0.14	0.14	0.14
Current Assets		140.23	75.06	94.00	60.09	12.50
Stocks		0.00	0.00	0.00	0.00	0.00
Debtors and prepaid expenses		23.76	4.48	24.32	2.50	2.50
Cash		108.25	62.40	61.21	49.12	1.52
Other		8.23	8.19	8.47	8.47	8.47
Current Liabilities		15.01	24.94	28.46	16.53	16.53
Creditors and accrued expenses		9.63	19.48	27.44	15.51	15.51
Short-term borrowings		0.00	0.00	0.00	0.00	0.00
Lease liabilities and others		5.38	5.45	1.02	1.02	1.02
Long-Term Liabilities		1.06	26.90	27.89	27.56	27.56
Long-term borrowings		0.00	0.00	0.00	0.00	0.00
Other long-term liabilities		1.06	26.90	27.89	27.56	27.56
Net Assets		126.52	176.19	194.32	172.03	123.75
CASH FLOW						
Operating Cash Flow		(117.56)	(100.18)	(89.20)	(103.12)	(47.59)
Net interest		0.00	0.00	0.00	0.00	0.00
Tax		0.00	0.00	0.00	0.00	0.00
Capex		0.00	0.00	0.00	0.00	0.00
Acquisitions/disposals		0.03	0.37	0.00	0.00	0.00
Financing		200.71	53.98	87.41	91.03	0.00
Dividends		0.00	0.00	0.00	0.00	0.00
Net Cash Flow		83.18	(45.82)	(1.79)	(12.09)	(47.59)
Opening net debt/(cash)		(24.00)	(108.25)	(62.40)	(61.21)	(49.12)
Other		1.06	(0.03)	0.61	0.00	0.00
Closing net debt/(cash)		(108.25)	(62.40)	(61.21)	(49.12)	(1.52)

Source: SynAct, Edison Investment Research

General disclaimer and copyright

This report has been commissioned by SynAct Pharma and prepared and issued by Edison, in consideration of a fee payable by SynAct Pharma. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2025 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
